Personalizing antipsychotic therapy to improve functional outcomes and quality of life

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

  1. Correll C. What are we looking for in new antipsychotics? J Clin Psychiatry 2011;72(suppl 1):9–13.
  2. Psychopharmacology Institute. Antipsychotics: the essentials. Available at: Accessed 23 October 2021
  3. Abidi A, et al. From chlorpromazine to clozapine—antipsychotic adverse effects and the clinician’s dilemma. Can J Psychiatry 2003;48:749–755.
  4. Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394:939–51.
  5. Wang J, et al. Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients. Neural Regeneration Research 2013;8(3):277–86.
  6. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951–62.
  7. Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacology 2011;0(0):1–54.
Du lämnar Progress in Mind Sverige
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Den här informationen är endast avsedd för hälso- och sjukvårdspersonal
Register for access to Progress in Mind in your country